Menu Close

Circle Wealth Management LLC Has $417,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Circle Wealth Management LLC cut its holdings in Eli Lilly and Company (NYSE:LLYGet Rating) by 13.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,458 shares of the company’s stock after selling 234 shares during the period. Circle Wealth Management LLC’s holdings in Eli Lilly and were worth $417,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of LLY. Norges Bank bought a new stake in Eli Lilly and in the fourth quarter worth $2,213,765,000. Capital World Investors boosted its holdings in Eli Lilly and by 13.9% in the fourth quarter. Capital World Investors now owns 19,115,896 shares of the company’s stock worth $5,280,206,000 after purchasing an additional 2,325,514 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in Eli Lilly and by 38.5% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,525,748 shares of the company’s stock valued at $1,254,743,000 after acquiring an additional 1,257,817 shares during the period. Vanguard Group Inc. boosted its holdings in Eli Lilly and by 1.8% during the first quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock valued at $20,183,695,000 after acquiring an additional 1,219,424 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Eli Lilly and by 54.8% during the first quarter. Arrowstreet Capital Limited Partnership now owns 3,311,713 shares of the company’s stock valued at $948,375,000 after acquiring an additional 1,172,504 shares during the period. 82.45% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent analyst reports. Morgan Stanley upped their price target on shares of Eli Lilly and from $395.00 to $412.00 and gave the company an “overweight” rating in a report on Wednesday. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. UBS Group upped their price objective on shares of Eli Lilly and to $335.00 and gave the company an “outperform” rating in a research report on Wednesday, July 27th. Barclays upped their price objective on shares of Eli Lilly and from $333.00 to $355.00 and gave the company an “overweight” rating in a research report on Thursday, July 7th. Finally, BMO Capital Markets upped their price objective on shares of Eli Lilly and from $369.00 to $396.00 and gave the company an “outperform” rating in a research report on Tuesday, September 6th. Three investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $330.44.

Insider Buying and Selling at Eli Lilly and

In other Eli Lilly and news, Director Jackson P. Tai acquired 656 shares of Eli Lilly and stock in a transaction on Friday, August 12th. The shares were purchased at an average cost of $304.19 per share, with a total value of $199,548.64. Following the completion of the purchase, the director now owns 62,857 shares in the company, valued at $19,120,470.83. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 89,458 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $332.85, for a total value of $29,776,095.30. Following the transaction, the insider now directly owns 103,875,441 shares of the company’s stock, valued at $34,574,940,536.85. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jackson P. Tai purchased 656 shares of Eli Lilly and stock in a transaction dated Friday, August 12th. The shares were purchased at an average cost of $304.19 per share, for a total transaction of $199,548.64. Following the completion of the transaction, the director now owns 62,857 shares of the company’s stock, valued at $19,120,470.83. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 753,125 shares of company stock valued at $242,744,201. 0.12% of the stock is currently owned by insiders.

Eli Lilly and Price Performance

LLY opened at $317.70 on Friday. Eli Lilly and Company has a one year low of $220.20 and a one year high of $335.33. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.10 and a quick ratio of 0.85. The company’s 50 day simple moving average is $317.94 and its 200-day simple moving average is $301.45. The stock has a market capitalization of $301.87 billion, a P/E ratio of 50.67, a price-to-earnings-growth ratio of 2.16 and a beta of 0.38.

Eli Lilly and (NYSE:LLYGet Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The company had revenue of $6.49 billion for the quarter, compared to the consensus estimate of $6.85 billion. During the same period last year, the company earned $1.87 earnings per share. Eli Lilly and’s revenue for the quarter was down 3.7% compared to the same quarter last year. Sell-side analysts anticipate that Eli Lilly and Company will post 7.97 earnings per share for the current fiscal year.

Eli Lilly and Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 9th. Shareholders of record on Monday, August 15th were paid a $0.98 dividend. The ex-dividend date was Friday, August 12th. This represents a $3.92 dividend on an annualized basis and a yield of 1.23%. Eli Lilly and’s payout ratio is presently 62.52%.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Receive News & Ratings for Eli Lilly and Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and and related companies with MarketBeat.com’s FREE daily email newsletter.